Aldose reductase inhibitors: the end of an era or the need for different trial designs?
about
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic miceRanirestat for the management of diabetic sensorimotor polyneuropathySorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance.Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors.Dual Delivery of NGF and bFGF Coacervater Ameliorates Diabetic Peripheral Neuropathy via Inhibiting Schwann Cells Apoptosis.Painful diabetic neuropathy.Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy.Diabetic neuropathy part 1: overview and symmetric phenotypesEndothelial dysfunction in diabetes.Nerve regeneration in diabetic neuropathy.Protein kinase C and the development of diabetic vascular complications.Measurement of somatic neuropathy for clinical practice and clinical trials.Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?Inhibition of aldose reductase by Gentiana lutea extracts.Transcriptome Profiles Using Next-Generation Sequencing Reveal Liver Changes in the Early Stage of Diabetes in Tree Shrew (Tupaia belangeri chinensis)The therapeutic potential of gene transfer for the treatment of peripheral neuropathies.The effects of C-peptide on type 1 diabetic polyneuropathies and encephalopathy in the BB/Wor-rat.Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs).Aldose reductase meets histone acetylation: a new role for an old player.Mechanism of diabetic neuropathy: Where are we now and where to go?Painful diabetic neuropathy: an updateContent validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathySystemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.A comparison of sural nerve conduction studies in patients with impaired oral glucose tolerance test.Mechanism of capsaicin inhibition of aldose reductase activity.Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations.Aldose reductase inhibitory activity studies of THERACURMIN.The aldo-keto reductase superfamily and its role in drug metabolism and detoxificationCurcumin, Cardiometabolic Health and DementiaTreatment of painful diabetic neuropathy: a review of the most efficacious pharmacological treatments
P2860
Q24530027-7E56B5FE-13E7-4BC3-BE77-D3468CB3DBB4Q28241270-675502FD-AEA3-480B-9EBF-D9309F129300Q31383595-48B18D77-E7CC-481D-929E-8FA8CF41F7D4Q33554440-6648E294-FCF3-4B98-A3BA-E19D988F913AQ33717786-58587E3C-7F47-4395-B4E6-00A93D4E7EB6Q33728732-68B2A751-5CF0-4B87-A452-1F26AEEBDD84Q33848421-36F64572-FFD3-4B27-8897-18A75D8BDA83Q33854046-93BFA0FE-D9D2-4FE8-A157-F4AFF5D64768Q33878023-4F352E2A-D585-409D-82B3-AEB4C69E727FQ33959485-2D1D32BD-FB71-44A3-A8C2-C76E86DC02FFQ34164146-BC13A59C-BD51-4F45-8626-E8243A712B09Q34570516-5169D51C-6F19-45E9-B235-99249F7E3100Q35087655-E7D0BE6A-3E13-4876-B0DF-B98C944BB07EQ35669992-7D946F25-01A8-4102-94BD-5928F7F0619CQ35946085-01E05697-3717-4391-ACA8-64E2FB85D6CBQ36111429-FE711B71-FDB8-49DA-83F5-E7E9B7151C84Q36741947-7EEB027D-CC1B-4BED-8624-CA61521ED4B2Q36762639-4BCD145C-585E-4A4A-A3CD-07F9485E4253Q37147785-C7B27377-BB3D-48E2-B783-4D8BD564D9C7Q37380241-96A33C47-4CAA-4C85-B0F6-A41BE8666E7FQ37510190-EE9D9578-CC8A-4342-8342-BB6A89921A51Q38213041-99F5CD37-E62E-4CDA-8BE7-109800A5CF4EQ38247947-4D342948-7DD3-4767-899E-42ED01376149Q38905482-436CFDEE-F697-4538-82D9-87F855207C02Q42050617-4840F152-B688-4A28-8EA8-AA4C2E7FF15EQ44252303-CD218BC7-4ED9-4B1A-965C-740C0A16A893Q44898251-60B07329-0625-4FF3-81FD-44B449A99551Q46912291-861944BF-F8F3-490A-975F-6060ACD24E48Q48300940-302F0D29-74BC-4A8B-8FCD-458955B0429BQ48580864-F91568FB-3999-4DFE-86EE-2B78E7DDA95DQ50208438-0BA2957C-E966-4202-8D91-747FEF61A78BQ56760512-3998253A-B1CA-42D0-829A-CE34612E6A71Q58699640-F6CC7FBB-3C12-481B-B0B4-8FD389165014Q58842272-CD9748D0-C0B8-4621-A9C4-053F9F28D262
P2860
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
@en
type
label
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
@en
prefLabel
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
@en
P2093
P356
P1433
P1476
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
@en
P2093
P356
10.2337/DIAB.46.2.S82
P407
P478
46 Suppl 2
P577
1997-09-01T00:00:00Z